/

NeoGenomics, Inc.

NEO US

NEO USNeoGenomics, Inc.

United States Composite

13.85

USD

-0.18

(-1.28%)

-0.70EPS Dil.

-19.76P/E

1.76BMarket Cap

Next Earnings

May 6

Held by Insiders

1.22%

Held by Institutions

100.87%

Short % of Float

5.50%

YTD Yield

-6.81%

3Y Yield

-74.04%

5Y Yield

-34.44%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

537

538

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

127

Market Capitalization

2,043

1,565

2,061

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

585

587

597

Cash, Cash Equivalents & STI

409

402

415

Accounts Receivable, Net

125

133

131

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

28.43%

17.33%

16.08%

Net Income, GAAP

0.00%

-368.89%

38.89%

Free Cash Flow

0.00%

-257.38%

68.04%

Total Cash Common Dividend

- -

Total Equity

65.31%

27.89%

-5.61%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

116

122

121

126

484

2022

117

125

129

139

510

2023

137

147

152

156

592

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.19

0.64

-0.17

-0.34

-0.07

2022

-0.40

-0.28

-0.30

-0.18

-1.16

2023

-0.25

-0.19

-0.15

-0.11

-0.70

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Christopher Michael Smith BSc
Full Time Employees: 2,100
Sector: Healthcare
Industry: Diagnostics & Research
Address: 9490 NeoGenomics Way Fort Myers FL United States 33912
IPO Date: Mar 16, 2004
Website: www.neogenomics.com
Business: NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Company News

Zacks
2 days ago
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
Zacks
3 days ago
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Yahoo
8 days ago
NeoGenomics Announces Senior Leadership Promotions
Zacks
16 days ago
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Yahoo
16 days ago
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Yahoo
17 days ago
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
Yahoo
a month ago
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
Zacks
a month ago
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
Yahoo
a month ago
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
Zacks
a month ago
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
Yahoo
a month ago
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
Yahoo
a month ago
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report

Company Description

CEO: Mr. Christopher Michael Smith BSc
Full Time Employees: 2,100
Sector: Healthcare
Industry: Diagnostics & Research
Address: 9490 NeoGenomics Way Fort Myers FL United States 33912
IPO Date: Mar 16, 2004
Website: www.neogenomics.com
Business: NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Company News

Zacks
2 days ago
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
Zacks
3 days ago
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Yahoo
8 days ago
NeoGenomics Announces Senior Leadership Promotions
Zacks
16 days ago
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Yahoo
16 days ago
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Yahoo
17 days ago
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
Yahoo
a month ago
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
Zacks
a month ago
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
Yahoo
a month ago
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
Zacks
a month ago
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
Yahoo
a month ago
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
Yahoo
a month ago
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report